Insider · CIK 0001724605
Carole Ho
officer
Files at DNLI (Denali Therapeutics Inc.). First filing Jan 8, 2025, latest Jan 8, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $308k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
DNLI: Denali Therapeutics Inc.
DNLIOct 9, 2026 · close 19.45
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 44Moderate | Denali Therapeutics Inc. | $308k 15,162 shares | -8% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 6, 2025 | DNLI Denali Therapeutics Inc. | SOpen-market sale Common Stock | -12,255 | $20.22 | $248k | 178,580 | Jan 8, 2025 |
| Jan 7, 2025 | DNLI Denali Therapeutics Inc. | SOpen-market sale Common Stock | -2,907 | $20.81 | $60k | 175,673 | Jan 8, 2025 |
| Jan 3, 2025 | DNLI Denali Therapeutics Inc. | AGrant or award Common Stock | +54,180 | $0.00 | $0 | 190,835 | Jan 7, 2025 |
| Jan 3, 2025 | DNLI Denali Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +162,540 | $0.00 | $0 | 162,540 | Jan 7, 2025 |
| Nov 25, 2024 | DNLI Denali Therapeutics Inc. | MOption exercise Common Stock | +17,845 | $0.68 | $12k | 136,655 | Nov 27, 2024 |
| Nov 25, 2024 | DNLI Denali Therapeutics Inc. | MOption exercise Stock Option (right to buy)derivative | -17,845 | $0.00 | $0 | 107,155 | Nov 27, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.